Article Details
Retrieved on: 2024-06-04 18:26:41
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche's RHHBY immuno-oncology drug, Tecentriq (atezolizumab), in heavily ...
Article found on: uk.finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here